The Quarter in Review
Armata Pharmaceuticals (NYSEMKT:ARMP) has recently unveiled their financial results for the final quarter of 2023.
- The company reported an earnings per share of -55 cents, missing the mark set by analysts at -35 cents.
- On the revenue front, Armata Pharmaceuticals posted $1.53 million, exceeding analyst predictions by a staggering 77.67% ($860,000 estimate).
Automated Data at Work
InvestorPlace Earnings utilizes innovative data from TradeSmith to deliver real-time updates on quarterly earnings reports. Bringing to light pivotal insights like EPS and revenue figures, as well as a comparison to analyst projections. These reports are swift in their delivery, allowing our readers to stay informed amidst the ever-evolving financial landscape.
Closing Notes
View the original article on InvestorPlace Media, available at: https://investorplace.com/earning-results/2024/03/armp-stock-earnings-armata-pharmaceuticals-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC
